“The worldwide importance of the ongoing COVID-19 pandemic seems to naturally align our two vaccine institutes and provides the opportunity to build on this partnership,” said Jerome Kim, director general of the IVI based in Seoul.
The two research centres are partnering on a $180,000 project that will look at virus replication, immune responses, and the effect of antivirals and other medicines to combat COVID-19.
The USask funding for the initiative comes from the USask International Blueprint’s Global Innovation Fund and VIDO-InterVac.
South Korea has been one of the countries hardest hit by this virus. IVI has formed a number of partnerships with companies and governments to advance vaccines against the SARS-CoV-2 virus that causes COVID-19.
“This is a great example of the international partnerships needed to stop the global spread of this highly contagious virus,” said VIDO-InterVac Director Volker Gerdts.
The funding collaboration builds on a long-standing relationship between the two institutes, as well as on a recent memorandum of understanding (MOU) signed between USask President Peter Stoicheff and Director-General Kim in South Korea in October of 2019. Read more about the MOU here: https://news.usask.ca/articles/research/2019/usasks-vido-intervac-and-south-koreans-international-vaccine-institute-to-undertake-scientific-exchanges.php
The University of Saskatchewan is undertaking critical research and contributing to global efforts to combat COVID-19. The University of Saskatchewan's Vaccine and Infectious Disease Organization (VIDO-InterVac) is a world leader in developing vaccines and technologies to combat infectious diseases. Your support of the COVID-19 Research Fund supports the increased efforts of researchers at the University of Saskatchewan to develop vaccines and treatments for COVID-19. Donate now.